Stagnant growth, recurring disapprovals, generic reporting — the warning signs that your Google Ads agency isn't built for the peptide category, and how to switch safely.
Most peptide brands don't fire their Google Ads agency the moment something goes wrong. They wait — through a few disapprovals, a plateau they assume is "just the market," a policy flag that gets explained away. By the time the decision to switch is obvious, real revenue and often real account history has already been lost. Here's how to spot the warning signs early, before they become an emergency.
Generalist PPC agencies routinely take on peptide and research chemical clients without disclosing that they have no real experience in a restricted, healthcare-adjacent advertising category. It looks like standard ecommerce PPC from the outside. It isn't. The mismatch usually doesn't show up in the first month — it shows up three to six months in, once policy scrutiny accumulates and the agency's generalist playbook starts producing disapprovals instead of results.
Occasional disapprovals happen even to well-run accounts. A pattern of recurring disapprovals with no clear remediation plan — just resubmitting the same copy with minor tweaks — signals the agency doesn't understand what's actually triggering the reviews.
If you find out about a policy change from a disapproval notice rather than a heads-up from your agency, they're not monitoring policy updates. In this category, that's not a minor service gap — it's the core job.
Stale creative isn't just a performance problem. In a category where policy interpretation shifts, ad copy that hasn't been reviewed and refreshed against current guidance is a growing compliance liability, not just a missed optimisation opportunity.
A screenshot of spend, clicks, and ROAS with no commentary on account health, disapproval trends, or strategic next steps isn't reporting — it's a data export. You should be getting analysis, not just numbers.
If your account was switched to Target ROAS or Target CPA before it had meaningful conversion history, that's a fundamental strategic error that suggests the agency is applying a generic playbook rather than category-specific expertise.
Flat performance is sometimes market reality. But if your agency can't articulate a specific hypothesis for why growth has stalled and a specific plan to test it, that's a sign of managed decline rather than active management.
If you're forwarding your agency a Google policy update they hadn't already seen, the relationship has inverted. You're paying them to track this so you don't have to.
Ask what happens if your account manager is unavailable for two weeks. If the answer involves things grinding to a halt, there's no real operational resilience behind your account.
If pressed for case studies in this specific category and the agency pivots to generic ecommerce results, that's a direct signal their experience doesn't match what they're being paid to manage.
A suspension should trigger an active, documented appeal process — not a passive wait. If your agency's response to a ban was resignation rather than action, they don't have a remediation process, which means the same thing will happen again.
Switching agencies in this category carries a specific risk that doesn't apply to most other PPC niches: an abrupt, poorly managed transition can itself trigger account scrutiny. The safest path is an audit-first transition:
Don't repeat the mistake that got you here. Before signing with a new agency, run them through the same vetting process you should have used the first time — including asking directly about their peptide and research chemical account history, their cold-start bidding sequence, and their compliance monitoring process. We've laid out the full twelve-question vetting checklist here: Google Ads Agency for Peptides: The Complete 2026 Buyer's Guide.
The brands that make a clean switch to a specialized agency tend to see the difference quickly. One peptide brand scaled to $148K/month at a sustained 4.6x ROAS after a full-funnel rebuild of an account that had plateaued for six months under previous management. See the full case study. The plateau wasn't a market problem — it was an account structure and compliance problem that a specialized rebuild solved.
None of these ten signs in isolation means you need to fire your agency tomorrow. But if you're nodding along to three or more of them, the relationship has likely already cost you more in stalled growth and compliance risk than switching would cost in transition friction. The earlier you act on these signs, the less account history and momentum you have to rebuild.
We'll audit your current account — structure, compliance posture, and performance — and tell you plainly whether a switch is warranted and what a safe transition would look like. No charge, no commitment.
Or email directly: sveta@oney.studio
Oney Studio is a specialist Google Ads agency for peptide and research chemical brands. We build compliance-first account architecture that scales — from cold start to six-figure monthly revenue — without account-level policy flags.
Get a free 30-minute audit of your Google Ads or Meta Ads account. We’ll review compliance, structure, and growth opportunities — no strings attached.
Book a Free Audit